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incidence
Non-epithelial malignancies of the ovary account for 10% of
all ovarian cancers. Germ cell tumors (GCTs) are diagnosed
principally in young subjects whereas sex cord stromal tumors
(SCSTs) are more common in adult women. GCTs represent
5% of all ovarian neoplasms and 80% of preadolescent
malignant ovarian tumors. Sex cord stromal tumors are rare
neoplasms that account for 3–5 % of ovarian malignancies
and for the majority are functioning tumors with clinical
manifestations. The yearly adjusted incidence rate is 3.7/1000
000 and 2.1/1000 000 women for GCTs and SCSTs,
respectively.
diagnosis
The initial symptoms and signs of non-epithelial ovarian
cancers are usually characterized by subacute pelvic pain,
feeling of pelvic pressure due to the presence of a pelvic mass
and menstrual irregularities. Diagnostic work-up should
include pelvic ultrasound, abdomino-pelvic computed
tomography (CT scan), chest X-ray and PET scan for selected
cases. In young patients serum human chrorionic gonadotropin
(hCG), a-fetoprotein (AFP) titer and lactate dehydrogenase
(LDH), a complete blood count, and liver and renal function
tests should be determined. Inhibin is secreted by granulosa cell
tumors and is a useful marker for the disease. In case of
suspected gonadoblastomas a preoperative karyotype should be
obtained on all pre-menarche girls because of the propensity of
these tumors to arise in dysgenetic gonads.
The definitive diagnosis of non-epithelial ovarian cancer
requires a surgical specimen. Pathological diagnosis should be
made by a gynaecologic pathologist trained in ovarian cancer,
according to the World Health Organization classification.
The histologic subtypes are listed in Tables 1 and 2.
staging and risk assessment
The staging system for non-epithelial ovarian cancers is
generally adopted from that used for epithelial ovarian cancer
as originally defined by the Fe´de´ration Internationale de
Gyne´cologie et d’Obste´trique (FIGO). Surgery can be
performed through the open route or, in selected cases, by
laparoscopy. A careful examination of the abdominal cavity is
required. The staging procedure includes infracolic
omentectomy, biopsy of the diaphragmatic peritoneum,
paracolic gutters, pelvic peritoneum and peritoneal washings.
Systematic lymphadenectomy is not required; there is no
consensus about it. Only in cases of evidence of nodal
abnormality is node dissection required. A thorough surgical
staging for endodermal sinus tumor is not indicated because all
patients need chemotherapy. For SCSTs the retroperitoneal
evaluation is not mandatory because of the very low incidence
of retroperitoneal metastases in early stage [III, A]. Endometrial
curettage must be performed to rule out concomitant
uterine cancers in patient with granulosa cell tumor. Sertoli–
Leydig cell tumors are most frequently low-grade malignancies,
although occasionally a poorly differentiated variety may behave
more aggressively. The tumors typically produce androgens, and
clinical virilization is noted in 70–85% of patients.
Unilateral salpingo-oophorectomy with preservation of the
contralateral ovary and the uterus is now considered adequate
surgical treatment for patients with GCTs, even in cases of
advanced disease, because of the sensitivity of the tumor to
chemotherapy, and no systematic ovarian biopsy need be
performed where the contralateral ovary is macroscopically
normal. Conservative surgery also seems to be the appropriate
approach in young patients with SCSTs at stage I disease. For
postmenopausal women and in patients with advanced stage
disease or with bilateral ovarian involvement, abdominal
hysterectomy and bilateral salpingo-oophorectomy should be
performed with careful surgical staging.
Stage is the most important prognostic factor established to
date for SCSTs, in fact several article have reported that patients
with advanced disease have a significantly poorer survival rate.
For GCTs stage is an important prognostic factor as well,
though given their sensitivity to chemotherapy treatment even
more advanced stage disease can have a good prognosis.
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treatment plan
early stage disease, FIGO stage I–IIa
germ cell tumors. The majority of GCTs (60–70%) are
diagnosed at an early stage. Stage I patients have an excellent
prognosis (long-term disease-free status is 90%) and, after
adequate surgical staging, very often further adjuvant treatment
is not required. Therefore patients with stage Ia immature
teratoma or stage I pure dysgerminoma can be treated with
surgery only. All patients with stage I endodermal sinus are
treated with adjuvant chemotherapy. Data from the
English literature show that the most employed
combination therapy is bleomycin, etoposide and cisplatin
(BEP) [III, A].
sex cord stromal tumors. The majority of SCSTs (60–95%) are
at stage I at the time of diagnosis. Patients with stage I have an
excellent prognosis (long-term disease-free status is 90% of
the cases). The selection of early stage SCSTs patients for any
postoperative treatment is controversial. At present the relative
benefit of adjuvant chemotherapy has yet to be
demonstrated. Some authors would suggest adjuvant therapy
for stage Ic patients with high mitotic index SCST. In this
case platinum-based chemotherapy is the treatment of choice
[II–III].
advanced stage disease, FIGO stage IIb–IV
germ cell tumors. Patients with advanced stage disease should
undergo debulking surgery to remove as much gross tumor as
possible, but without major extensive procedures given the high
chemosensitivity of these tumors. Platinum-based regimens
have been the treatment of choice over the past decade for
GCTs, with the BEP regimen becoming the most widely used.
The optimal duration of therapy is still under debate, but
generally many investigators believe that three cycles of BEP
with completely resected disease and four cycles for patients
with macroscopic residual disease seem appropriate [III, A].
Even though dysgerminomas are very sensitive to radiation
therapy there is no evidence to support the use of adjuvant
radiation therapy for advanced stage GCTs.
sex cord stromal tumors. Debulking surgery, whenever feasible,
remains the most effective treatment for metastatic or recurrent
granulosa cell tumors. Platinum-based chemotherapy is
currently used for patients with advanced stage SCSTs or
recurrent disease, with an overall response rate of 63–80%.
There are limited data regarding the utility of chemotherapy in
patients with persistent Sertoli–Leydig tumor, but responses in
patients with measurable disease have been reported. The
BEP regimen for 3–6 cycles is currently recommended for
adjuvant postoperative chemotherapy and for patients with
recurrent SCSTs. Taxanes demonstrated an interesting activity
in SCSTs with a favorable toxicity profile [III, A]. Taxane
and platinum combination chemotherapy seems to be a
reasonable candidate for future trials. Little evidence exists for
the use of hormonal therapy or radiation therapy and these
modalities should be restricted to selected cases.
response evaluation
Serum tumor markers (hCG, AFP, LDH, CA125 and inhibin)
can accurately correlate with tumor response during
chemotherapy. CT scan of the abdomen, pelvis and chest (in
case of suspected lung metastases) and pelvic ultrasound are the
most common and useful imaging methods to evaluate the
response to chemotherapy in patients with measurable disease.
follow-up
Approximately 75% of GCT recurrences occur within the first
year after initial treatment; the most common site is the
peritoneal cavity and more rarely the retroperitoneal lymph
nodes.
In contrast, the indolent nature of SCSTs with a tendency to
late recurrence (median time to relapse is 4–6 years), requires
long-term surveillance. Several reports describe relapses
occurring >20 years (up to 37 years) after diagnosis. Common
sites of recurrence are the upper abdomen (55–70%) and the
pelvis (30–45%).
The follow-up visit must include history, physical
examination with pelvic examination and tumor markers every
3 months for the first 2 years, and every 6 months during years
3–5 or until progression is documented. Pelvic ultrasound
should be performed every 6 months in those patients who
Table 1. Classification of germ cell ovarian tumors
Dysgerminoma
Teratoma
Immature
Mature
Monodermal and highly specialized
Endodermal sinus tumor
Embryonal carcinoma
Polyembryoma
Choriocarcinoma
Mixed forms
Table 2. Classification of sex cord stromal ovarian tumors
Granulosa-stromal cell tumors
Granulosa cell tumors
Adult type
Juvenile type
Tumors in the thecoma–fibroma group
Thecoma
Fibroma–fibrosarcoma
Sclerosing stromal tumor
Sertoli–Leydig cell tumors (androblastomas)
Sertoli cell tumors
Leydig cell tumor
Sertoli–Leydig cell tumors
Gynandroblastoma
Sex cord tumor with anular tubules
Unclassified
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underwent fertility sparing surgery, whereas CT scan of the
abdomen and pelvic is usually performed yearly.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts and
the ESMO Faculty.
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